The pancreas is made up of exocrine cells (cells that secrete digestive enzymes) and cells that secrete hormones such as insulin. The new study is the first to focus on the role of Sirtuin-1 in exocrine cells, which can develop into pancreatic tumours.
In normal exocrine cells, the behaviour of Sirtuin-1 is inhibited by another protein. During the development of pancreatic cancer, Sirtuin-1 disconnects from that inhibitor, giving it the freedom to interact with other proteins that may help the cancer to develop, and the cancer cells to survive.
Dr Elke Wauters, from the Diabetes Research Centre at the Free University of Brussels in Belgium, and Dr Ilse Rooman, also affiliated with the Free University of Brussels as well as a scientist at Sydney’s Garvan Institute of Medical Research, are the first to study Sirtuin-1 in the initiation and progression of pancreatic cancer. After examining its behaviour in mouse models and in cell cultures from human tumours, they believe that inhibiting Sirtuin-1 may help prevent the initiation of pancreatic cancer, as well as prevent the further growth of established tumours. Their results are published in Cancer Research, now online.
“While this is basic science, we believe our findings are important in progressing the understanding of how pancreatic tumours develop and may translate into new therapeutic strategies,” said Dr Ilse Rooman.
“Sirtuin-1 inhibitors are already in Stage 2 Clinical Trials for another disease, meaning that they have been shown to be safe for people. That is excellent news as far as we are concerned, because it takes so much money and time to get a drug to that stage, and we believe this type of drug might be important in treating pancreatic cancer.”
“Sirtuin-1 is a multi-faceted molecule, playing different roles in different tissue and cell types, and its activation has been shown to have benefits in metabolic disease and in some other cancers. While we don’t address this point in our paper, there are also Clinical Trials underway for drugs that activate Sirtuin-1, especially for treating type 2 diabetes, and we believe it’s important to signal its potential harm as far as pancreatic cancer is concerned.”
“The next stage of our work will be to further test our hypothesis in preclinical models.”
The Garvan Institute of Medical Research was founded in 1963. Initially a research department of St Vincent’s Hospital in Sydney, it is now one of Australia’s largest medical research institutions with over 600 scientists, students and support staff. Garvan’s main research areas are: Cancer, Diabetes & Obesity, Immunology and Inflammation, Osteoporosis and Bone Biology and Neuroscience. Garvan’s mission is to make significant contributions to medical science that will change the directions of science and medicine and have major impacts on human health. The outcome of Garvan’s discoveries is the development of better methods of diagnosis, treatment, and ultimately, prevention of disease.
Media enquiries should be directed to:
Science Communications Manager
M: + 61 434 071 326
P: +61 2 9295 8128
E: a.heather “a” garvan.org.au